{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-173796","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2023-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.968613+00:00","generated_at":"2026-06-13T18:08:24.109104+00:00","sec_items":["5.07","8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Enliven Therapeutics recasts FY2022 financials after reverse split; reports net loss of $37.7M","bullets":["Annual meeting elected directors Heyman and Kintz; ratified Deloitte & Touche as auditor for FY2023.","Recasted FY2022 net loss of $37.7M ($12.05 per share) vs $24.7M in FY2021.","R&D expense rose 51% to $31.0M; G&A expense increased to $7.8M.","Cash and equivalents totaled $75.5M at Dec 31, 2022, down from $110.0M a year earlier.","Company expects current cash to fund operations for at least 12 months from March 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-173796","json":"https://secwatch.observer/filing/0001193125-23-173796.json","markdown":"https://secwatch.observer/filing/0001193125-23-173796.md","text":"https://secwatch.observer/filing/0001193125-23-173796.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000119312523173796/0001193125-23-173796-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000119312523173796/d514661d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T18:08:24.109104+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6799ee2595cbc32e777f87fd4d68fa7aeb9e1cc0","claim":"Enliven Therapeutics, Inc. shareholders approved Election of two Class III Directors at the 2023-06-23 meeting.","evidence_excerpt":"Name of Director For Withheld Broker Non-Votes Richard Heyman, Ph.D. 30,518,067 385,508 1,641,388 Samuel Kintz, M.B.A. 30,900,278 3,297 1,641,388","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1672619/000119312523173796/0001193125-23-173796-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-23"}],"fact_type":"shareholder_vote"},{"claim_id":"c6c64b8ff0e00c76fdd38210c731ed58063c7c4c","claim":"Enliven Therapeutics, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2023-06-23 meeting.","evidence_excerpt":"For Against Abstain 32,543,338 1,460 165","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1672619/000119312523173796/0001193125-23-173796-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-23"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}